JOHCM EMERGING MARKETS SMALL MID CAP EQUITY FUND CLASS I (JOMEX US) stock market data APIs
14.9507
0(0%)
as of July 3, 2025
Try our APIs with
free plan!
JOHCM EMERGING MARKETS SMALL MID CAP EQUITY FUND CLASS I Financial Data Overview
Price chart is built with
Anychart
Prev. Close
14.9507
Open
14.9507
High
14.9507
Low
14.9507
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get JOHCM EMERGING MARKETS SMALL MID CAP EQUITY FUND CLASS I data using free add-ons & libraries
End-of-day & Earnings data
Get JOHCM EMERGING MARKETS SMALL MID CAP EQUITY FUND CLASS I Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get JOHCM EMERGING MARKETS SMALL MID CAP EQUITY FUND CLASS I End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
JOHCM EMERGING MARKETS SMALL MID CAP EQUITY FUND CLASS I News
New
Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
CARMIEL, Israel, March 4, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization...
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
Study achieved key objectives for safety, efficacy and pharmacokinetics After completion of the study, all patients enrolled in an extension study pegunigalsidase alfa (PRX-102) provided coverage to...
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Is About To Turn The Corner
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Protalix BioTherapeutics, Inc., a biophar...
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
Anticipated PDUFA for PRX-102 in Fabry disease currently set for April 27, 2021 Company, with its Commercialization Partner, Chiesi, poised to commercialize PRX-102 Additional data and milestones ex...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
